Invitation to Roche’s Virtual Oncology/SABCS Investor Event Mittwoch, 26. November 2025 - 10:01

We are pleased to invite investors and analysts to participate in our virtual event on Thursday, 11 December 2025, to highlight new results from Roche's breast cancer pipeline, including data from the Phase III lidERA breast cancer study evaluating giredestrant as an adjuvant endocrine treatment for people with ER+/HER2- BC that will be presented at the 48th San Antonio Breast Cancer Symposium (SABCS) from 9-12 December 2025.

16:30 - 17:30 CET / 15:30 - 16:30 GMT
10:30 - 11:30 am EST / 07:30 - 08:30 am PST

Agenda

Introduction
Bruno Eschli, Head of Investor Relations

Breast cancer franchise update
Maura Dickler, VP, Global Head for Breast & Gynecologic Cancers, Product Development

Ph III (lidERA) giredestrant in adjuvant ER+/HER2-negative, early BC
Aditya Bardia, MD, MPH, FASCO, Professor of Medicine, Geffen School of Medicine,
University of California Los Angeles

Q&A

The slides will be available for download at 15:30 CET on the day of the event. > click here

Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,

Bruno Eschli
Head of Investor Relations

Loren Kalm
Head of Investor Relations, North America

Roche Investor Relations

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com

Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com